Shares of Theravance Inc. (NASDAQ: THRX) rallied on Monday after a report from the U.S. drug regulators showed that the once-a-day lung disease treatment Breo Ellipta, which the company is developing in conjunction with the GlaxoSmithKline Plc, might get an approval.
Continue reading Major Movers on April 15; THRX, ACOR, LIFE, TMO, NGD, ABX, GG, WLT, S